Two-thirds of men with intermediate-risk prostate cancer and nearly half of men with high-risk cancer are receiving treatment ...

At the same time, aggressive treatment declined in men with low-risk prostate cancer as might have been expected in an era ...

Prostate cancer is a growing problem in men, and advanced cases are rising for the first time in 20 years, which is why ...

In a study of US veterans, the authors say many would benefit from conservative management and active surveillance over ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new ...

Even accounting for age-related symptoms and disease, treatment of prostate cancer came with higher rates of complications ...

Prostate cancer treatment guidelines recommend against aggressive therapy for those with a life expectancy of less than 10 years.

Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments that carry risks of side effects that can significantly reduce the quality ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Scientists uncover functionality of a genetic variant in the prostate specific antigen (PSA) gene to improve the current diagnostic test to help distinguish aggressive from non-aggressive prostate ...

According to the 2019 National Cancer Registry the lifetime risk for prostate cancer in South Africa is 1 in every 15 man. Prostate cancer is the most common cancer in men globally and is showing a ...